

DRUG PRIOR AUTHORIZATION COMMITTEE

June 18, 2009

TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update PDL Process Discussion	George L. Oestreich/ Andrew Haslag
11:30 - 11:35	DUR Update	Tisha McGowan

Old Business

11:35 - 12:05	a. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Jay Bryant Wimp
---------------	--	-----------------

New Business

12:05 – 12:20	New Drug/Product Reviews	
	a. Proposed Actions (See website and Attached Summary)	Jay Bryant Wimp
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	

a. **Clinical Edits**

i. **Maraviroc/Trofile**

- Discussion
- Public Hearing
- Decision

ii. **Suboxone Clinical Edit Changes**

- Discussion
- Public Hearing
- Decision

iii. **Xolair Clinical Edit Changes**

- Discussion
- Public Hearing
- Decision

12:20-1:45	<i>Proposed New Program Actions of Existing Products</i>	
------------	--	--

a. **Drug List (PDL)**

i. **Beta Blockers**

- Discussion
- Public Hearing
- Decision

ii. **Calcium Channel Blockers/Dihydropyridines**

- Discussion
- Public Hearing
- Decision

iii. **Calcium Channel Blockers/ Non-Dihydropyridines**

- Discussion
- Public Hearing
- Decision

iv. **Calcium Channel Blocker/ARB Combinations**

- Discussion
- Public Hearing
- Decision

v. **Cox II Inhibitors**

- Discussion
- Public Hearing
- Decision

vi. **Hepatitis C Agents**

- Discussion
- Public Hearing
- Decision

- Decision
 - vii. **Amylin Analogs**
 - Discussion
 - Public Hearing
 - Decision
 - viii. **GLP -1 Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
 - ix. **DPP-IV Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
 - x. **Onychomycosis Antifungals**
 - Discussion
 - Public Hearing
 - Decision
 - xi. **Proton Pump Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
 - xii. **Ribavirins**
 - Discussion
 - Public Hearing
 - Decision
 - xiii. **Topical Immunomodulators**
 - Discussion
 - Public Hearing
 - Decision
 - xlv. **Topical Androgen Agents**
 - Discussion
 - Public Hearing
 - Decision
- c. **Preferred Drug List**
- i. Process discussion
 - ii. Therapeutic classes-to be *announced at meeting*

1:45

LUNCH

2:00-2:20

Program Utilization Information

2:20-2:30

Other Business

- i. *Top 25" Drugs by Cost*
- ii. *Clinical Edit Summary Report*
- iii. *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

2:30-2:35

Minutes Review

Discussion/Approval

2:35-3:00

Case Reviews

Rhonda Driver

NEXT MEETING: September 17, 2009 – 205 Jefferson Street, 10th Floor